Fig. 9. Biodistribution of 89Zr-labeled trastuzumab immunoconjugates in normal male C57Bl/6j mice at 6 h (
), 1 day (
), 3 days (
), and 7 days (
) post-injection. Top: Biodistribution for animals administered 89Zr-YM103-trastuzumab; Bottom: Biodistribution for animals administered 89Zr-DFO-trastuzumab. Error bars correspond to standard error of the mean, (n = 3 for each timepoint). Notably, animals administered 89Zr-YM103-trastuzumab demonstrated significantly higher bone uptake and lower blood pool retention compared to animals administered 89Zr-DFO-trastuzumab over the course of the experiment. This is indicative of the lower in vivo stability of the 89Zr-chelate in 89Zr-YM103-trastuzumab compared to 89Zr-DFO-trastuzumab.
